Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | HINT1 | P49773 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18022452 | 0.91 | HPGD (0.39) | HPGDIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL16368022 | 0.83 | POLRMT (0.47) | IMPDH2IMPDH1TAS1R3TAS1R1ADORA3 | |
| SCHEMBL18022453 | 0.81 | HINT1 (0.49) | ADORA3HINT1NT5ESTING1TGM2 | |
| SCHEMBL16214160 | 0.80 | ADORA3 (0.52) | HPGDADORA3HINT1NT5ESTING1 | |
| SCHEMBL15798626 | 0.80 | ADORA3 (0.52) | HPGDADORA3HINT1NT5ESTING1 | |
| SCHEMBL13523557 | 0.80 | ADORA3 (0.52) | HPGDADORA3HINT1NT5ESTING1 | |
| SCHEMBL16214156 | 0.78 | ADORA3 (0.35) | HPGDIMPDH2IMPDH1TAS1R3TAS1R1 | |
| Phosphoric Acid SCHEMBL21465165 | 0.78 | NT5E (0.50) | ADORA3HINT1NT5ESTING1TGM2 | |
| SCHEMBL16214131 | 0.78 | TYMP (0.42) | HPGDIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL16214071 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237106-A1 | 4'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF EBOLA VIRUS RNA REPLICATION | RIBOSCIENCE LLC (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237106-A1 | 4'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF EBOLA VIRUS RNA REPLICATION | RNMT, RNGTT, EIF2AK2 | HPGD 2775/4885IMPDH2 162/4885IMPDH1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.